CHC (4164) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 承業醫

CHC (4164) reported revenue of NT$346.2 million for Oct 2026, +2.5% year on year and -31.6% from the previous month. Revenue for Jan–Oct 2026 was NT$3.84 billion (+9.0% year on year).

In Oct 2026, it ranked No. 27 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$237.5 million24/10Nov 2024 NT$297.1 millionDec 2024 NT$486 millionJan 2025 NT$227.6 millionFeb 2025 NT$218.9 million25/02Mar 2025 NT$558.3 millionApr 2025 NT$249.9 millionMay 2025 NT$301.6 millionJun 2025 NT$533.4 million25/06Jul 2025 NT$287.4 millionAug 2025 NT$283.8 millionSep 2025 NT$527.9 millionOct 2025 NT$337.8 million25/10Nov 2025 NT$394.1 millionDec 2025 NT$477.6 millionJan 2026 NT$314.7 millionFeb 2026 NT$268.7 million26/02Mar 2026 NT$577.1 millionApr 2026 NT$304.4 millionMay 2026 NT$543.5 millionJun 2026 NT$329.9 million26/06Jul 2026 NT$326.5 millionAug 2026 NT$327.6 millionSep 2026 NT$506.4 millionOct 2026 NT$346.2 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$346.2 million+2.5%-31.6%
Sep 2026NT$506.4 million-4.1%+54.6%
Aug 2026NT$327.6 million+15.4%+0.3%
Jul 2026NT$326.5 million+13.6%-1.0%
Jun 2026NT$329.9 million-38.2%-39.3%
May 2026NT$543.5 million+80.2%+78.6%
Apr 2026NT$304.4 million+21.8%-47.3%
Mar 2026NT$577.1 million+3.4%+114.8%
Feb 2026NT$268.7 million+22.8%-14.6%
Jan 2026NT$314.7 million+38.3%-34.1%
Dec 2025NT$477.6 million-1.7%+21.2%
Nov 2025NT$394.1 million+32.6%+16.7%
Oct 2025NT$337.8 million+42.2%-36.0%
Sep 2025NT$527.9 million+9.1%+86.0%
Aug 2025NT$283.8 million+10.6%-1.2%
Jul 2025NT$287.4 million+29.1%-46.1%
Jun 2025NT$533.4 million+46.5%+76.9%
May 2025NT$301.6 million-21.7%+20.7%
Apr 2025NT$249.9 million+14.0%-55.2%
Mar 2025NT$558.3 million+151.1%+155.1%
Feb 2025NT$218.9 million+30.8%-3.8%
Jan 2025NT$227.6 million-11.7%-53.2%
Dec 2024NT$486 million+32.1%+63.6%
Nov 2024NT$297.1 million-22.1%+25.1%
Oct 2024NT$237.5 million-66.2%-50.9%

Jan–Oct 2026 cumulative: NT$3.84 billion (+9.0% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: CHC vs PEC / CHC vs Lotus Pharm / CHC vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16